| __timestamp | Gilead Sciences, Inc. | Regeneron Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2983000000 | 504755000 |
| Thursday, January 1, 2015 | 3426000000 | 838526000 |
| Friday, January 1, 2016 | 3398000000 | 1177697000 |
| Sunday, January 1, 2017 | 3878000000 | 1320433000 |
| Monday, January 1, 2018 | 4056000000 | 1556200000 |
| Tuesday, January 1, 2019 | 4381000000 | 1834800000 |
| Wednesday, January 1, 2020 | 5151000000 | 1346000000 |
| Friday, January 1, 2021 | 5246000000 | 1824900000 |
| Saturday, January 1, 2022 | 5673000000 | 2115900000 |
| Sunday, January 1, 2023 | 6090000000 | 2631300000 |
| Monday, January 1, 2024 | 6091000000 | 2954400000 |
Infusing magic into the data realm
In the competitive landscape of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Gilead Sciences, Inc. and Regeneron Pharmaceuticals, Inc. have demonstrated contrasting trends in their SG&A expenditures.
From 2014 to 2023, Gilead's SG&A costs surged by over 100%, peaking at approximately $6.1 billion in 2023. This represents a consistent upward trajectory, reflecting Gilead's aggressive expansion and marketing strategies. In contrast, Regeneron's SG&A expenses grew at a more moderate pace, increasing by about 420% to reach $2.6 billion in the same period.
This divergence highlights differing strategic priorities: Gilead's focus on broadening its market reach versus Regeneron's emphasis on cost efficiency. As the biotech industry evolves, these financial strategies will play a pivotal role in shaping each company's future success.
Selling, General, and Administrative Costs: Johnson & Johnson vs Gilead Sciences, Inc.
Cost Management Insights: SG&A Expenses for Gilead Sciences, Inc. and Takeda Pharmaceutical Company Limited
Gilead Sciences, Inc. vs United Therapeutics Corporation: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Gilead Sciences, Inc. and ImmunityBio, Inc.
Gilead Sciences, Inc. vs Novavax, Inc.: SG&A Expense Trends
Selling, General, and Administrative Costs: Regeneron Pharmaceuticals, Inc. vs Biogen Inc.
Operational Costs Compared: SG&A Analysis of Regeneron Pharmaceuticals, Inc. and BioMarin Pharmaceutical Inc.
Who Optimizes SG&A Costs Better? Regeneron Pharmaceuticals, Inc. or Dr. Reddy's Laboratories Limited
Who Optimizes SG&A Costs Better? Regeneron Pharmaceuticals, Inc. or Ultragenyx Pharmaceutical Inc.
Comparing SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Amicus Therapeutics, Inc. Trends and Insights
Regeneron Pharmaceuticals, Inc. and Vericel Corporation: SG&A Spending Patterns Compared
Selling, General, and Administrative Costs: Regeneron Pharmaceuticals, Inc. vs Evotec SE